Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?   

Would you use MRD status to guide your decision making? 



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Chicago
Excellent points about ixazomib and for showcasing...
Sign in or Register to read more